Cogstate Ltd · ASX:CGS
Cogstate — Investor Presentation (September 2017)
27 slides from Cogstate's investor presentation, September 2017
Slide 1: Investor Presentation
Investor Presentation September 2017 © 2017 Cogstate Ltd. All rights reserved.
Slide 2: Mission statement on brain health measurement
“ We believe that brain health is profoundly important to quality of life and should be easier to measure. That’s why we so passionately apply our expertise, access to data and flexible technology to simplify the measurement of cognition.” 2
Slide 3: Investment Highlights
Investment Highlights (refer to slides) • Advanced commercial opportunities based upon 15+ years of world-class 4-6 research and development • Continued revenue growth and positive cash flow, with planned investment in 7-8 strategic areas • Expansion of Clinical Trials commercial opportunity: 9 – 13
Slide 4: Corporate Overview
Corporate Overview Strong conviction from long-term shareholders has enabled Cogstate to develop a unique technology platform, extensive validation & expanding supporting services. Highly credentialed and well aligned Board and Trading information management team holding >40% of Cogstate shares Shar
Slide 5: Leaders In Cognitive Measurement
Leaders In Cognitive Measurement Digital brain health assessments and novel technology enhancements for traditional cognitive measures, all driven by science and operational expertise Our proven technology allow clients to We are commercialising our technology measure cognition with greater fidelity
Slide 6: Validated Through Use in Over 1,500 Studies Across Academic and Clinical Research
Validated Through Use in Over 1,500 Studies Across Academic and Clinical Research >50 >90 Countries Languages & Dialects >400 >70 Peer Reviewed Indications Publications 6
Slide 7: FY17 Financial Highlights
FY17 Financial Highlights A Solid Year with Growth Across Most Core Metrics Sales contracts executed Contracted future revenues US$29.6m A$37.5m (US$28.7m) Contract delays in second half pushed Strong contracted revenue pipeline +4% awards into FY18 +10% Revenue EBITDA A$35.0m (US$26.5m) A$0.1m (US$
Slide 8: Investments for Future Growth
Investments for Future Growth Investments to facilitate continued future growth within the Clinical Trials segment as well as the launch into Clinical Practice in FY18. FY17 FY16 A$ A$ Healthcare ($1.23m) ($0.97m) - preparation for FDA submission and commercial launch of Cognigram (commercial launch
Slide 9: Expanded Commercial Opportunities In Clinical Trials
Expanded Commercial Opportunities In Clinical Trials 9
Slide 10: Commercial Success Metrics
Commercial Success Metrics Clinical Trials Profit Contribution ! 40,000,000 34,652,048 35,000,000 30,000,000 27,140,935 Building Pipeline For Future Growth 25,000,000 20,000,000 19,092,047 • Sales pipeline now exceeds US$100m AUD $ 15,702,044 15,775,169 15,000,000 • Preferred partner for Lilly AD pr
Slide 11: Complete Solutions for More Reliable Results
Complete Solutions for More Reliable Results Scientific Consulting Computerised Scale Assessment Management Reliable Data For Clinical Trial Decision-making Central Monitoring Rater Training Enhanced eCOA 11
Slide 12: Enhanced Solutions Delivered in FY17
Enhanced Solutions Delivered in FY17 Computerized Cognitive Tablet-based Rater Training Assessment eSource & Monitoring Partnered with Clinical Ink to provide Created a novel eLearning solution Adapted our technology for more that drives efficiencies in the training, flexible, device-independent eSo
Slide 13: Global Footprint and Managed Growth
Global Footprint and Managed Growth Global Footprint Total Headcount & Active Trials 175 London, UK Boston, MA 107 New Haven, CT Headcount 80 New York, NY 75 # of Trials 63 54 57 44 2014 2015 2016 2017 Melbourne, AU • ~275 team • Managed growth, hiring ahead of demand - 175 full-time employees acros
Slide 14: FDA Clearance for U.S. Healthcare Market
FDA Clearance for U.S. Healthcare Market 14
Slide 15: What Is Cognigram?
What Is Cognigram? • 10-15 minute test for clinical care setting • Can be taken at home or in hospital/clinic • Assessment results instantly available to healthcare professionals • Class II medical device, reviewed and cleared by FDA • HIPAA compliant Sensitivity Ease of use Culturally Impairment Wi
Slide 16: Most Promising Clinical Applications
Most Promising Clinical Applications Application Benefits Detect cognitive decline that • early detection for disease management could be signs of Alzheimer’s or and clinical trial referral Mild Cognitive Impairment • evaluate cognitive state Monitor Drug Side Effect during/after drug therapy • redu
Slide 17: Cognigram Report for Healthcare Professionals
Cognigram Report for Healthcare Professionals Patient & assessment order Information Interactive results and data visualisations Real-time baseline configuration and change score analysis Composite scores (shown) and detailed outcome measures 17
Slide 18: Enhanced Leadership & Expertise
Enhanced Leadership & Expertise 18
Slide 19: Senior Executive Appointments
Senior Executive Appointments To Further Accelerate Revenue Growth in Clinical Trials and Healthcare George Hunnewell Frank Cheng COO & President of Clinical Trials President of Healthcare Appointed November 2016 (US based) Appointed November 2016 (US based) ▪ 25 years experience growing healthcare
Slide 20: Non-Exec Director Appointments
Non-Exec Director Appointments Providing Enhanced Commercial and Governance Oversight Richard Mohs Jane McAloon Independent non-executive director Independent non-executive director Appointed January 2017 (US based) Appointed January 2017 (Aust based) ▪ Retired from Eli Lilly in 2015, where he held
Slide 21: FY18 Goals and Objectives
FY18 Goals and Objectives Continued Investment to Position for the Longer-term Opportunity • Increase in Clinical Trial sales, driven by more than 100% growth in sales pipeline • Increased contribution from the Clinical Trials segment • Launch and roll-out of Cognigram • Investment in Healthcare; we
Slide 22: Cogstate
oi Cogstate
Slide 23: Appendix: background information
Appendix: background information Additional investor presentations available at : cogstate.com/investors/investor-presentations/ 23
Slide 24: FY17 Summary of Financial Performance
FY17 Summary of Financial Performance * *Other operating expenditure, includes employment expenses of A$4.9m (FY16 A$4.6m) inclusive of Board, CEO, COO, Finance team, Legal team, administrative and temporary staff. Those employment expenses are expected to remain consistent from FY17 to FY18. Additi
Slide 25: Market Opportunity
Market Opportunity $800m Annual Opportunity for Cognition Assessment in Clinical Trials Clinical trials context Three key applications in efficacy, safety, and screening worth >US$500m annually in US clinical trials Large and growing clinical research market… Approximate Estimated Potential value to
Slide 26: World Class Customer Base
World Class Customer Base Cogstate is a Key Partner to the World’s Leading Pharmaceutical Companies Worked with 15 of the top 20 pharmaceutical 76% of new clinical trials contracts are companies over the last 2 years signed by repeat clients Why do clients continue to choose Cogstate? ✓ End-to-end o
Slide 27: Validated & Scalable Technology Platform
Validated & Scalable Technology Platform 15+ years of investment in Cogstate’s scalable technology platform underpins accelerating commercial success and provides foundation for further growth Validated approach Valuable databases Built for growth Technology is clinically and Unique proprietary data